Established and potential strategies against papillomavirus infections

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 2, 2004, Pages 137-139

  Bernard, Hans Ulrich ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer of the cervix; Cidofovir; Interferon; Vaccination; Warts

Indexed keywords

3 INDOLEMETHANOL; ALPHA INTERFERON; AMINOLEVULINIC ACID; ANTIVIRUS AGENT; ASCORBIC ACID; BETA CAROTENE; CIDOFOVIR; CISPLATIN; DNA VACCINE; FLUOROURACIL; FOLIC ACID; HEMATOPORPHYRIN DERIVATIVE; IMIQUIMOD; INTERFERON; PLACEBO; PODOPHYLLIN; PODOPHYLLOTOXIN; PROTEIN E6; PROTEIN E7; PROTEIN P53; RETINOL; TRANSCRIPTION FACTOR; TRICHLOROACETIC ACID; VIRUS DNA; VIRUS PROTEIN; VIRUS VACCINE;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONDYLOMA; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; GENITAL TRACT CANCER; HUMAN; IMMUNE SYSTEM; LARYNX DISORDER; NONHUMAN; RECURRENCE RISK; SIDE EFFECT; SURGICAL APPROACH; UTERINE CERVIX CANCER; VACCINATION; VERRUCA VULGARIS; VIRUS INFECTION; VIRUS REPLICATION; VIRUS TRANSCRIPTION; VIRUS TRANSFORMATION; WART VIRUS;

AMINOQUINOLINES; ANTIMETABOLITES; ANTIVIRAL AGENTS; CYTOSINE; DRUG DESIGN; FLUOROURACIL; HUMANS; INDOLES; INTERFERON INDUCERS; INTERFERONS; ORGANOPHOSPHORUS COMPOUNDS; PAPILLOMAVIRUS INFECTIONS; PHOSPHONIC ACIDS; PODOPHYLLIN; VIRAL VACCINES;

EID: 1242352914     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh023     Document Type: Article

References (19)

1. Bernard, H. U. (2002). Gene expression of genital human papillomaviruses and potential antiviral approaches. Antiviral Therapy 7, 219-37.
2. Shikowitz, M. J., Abramson, A. L., Freeman, K. et al. (1998). Efficacy of DHE photodynamic therapy for respiratory papillomatosis: immediate and long-term results. Laryngoscope 108, 962-7.
3. Wiley, D. J., Douglas, J., Beutner, K. et al. (2002). External genital warts: diagnosis, treatment, and prevention. Clinical Infectious Diseases 35, S210-24.
4. Stanley, M. A. (2002). Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clinical and Experimental Dermatology 27, 571-7.
5. Jin, L., Qi, M., Chen, D. Z. et al. (1999). Indole-3-carbinol prevents cervical cancer in human papilloma virus type 16 (HPV16) transgenic mice. Cancer Research 59, 3991-7.
6. Follen, M., Vlastos, A. T., Meyskens, F. L. et al. (2002). Why phase II trials in cervical chemoprevention are negative: what have we learned? Cancer Causes & Control 13, 855-73.
7. Abdulkarim, B., Sabri, S., Deutsch, E. et al. (2002). Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene 21, 2334-46.
8. De Clercq, E., Andrei, G., Balzarini, J. et al. (1999). Antitumor potential of acyclic nucleoside phosphonates. Nucleosides & Nucleotides 18, 759-71.
9. Syed, T. A., Qureshi, Z. A., Ahmad, S. A. et al. (2000). Management of intravaginal warts in women with 5-fluorouracil (1%) in vaginal hydrophilic gel: a placebo-controlled double-blind study. International Journal of STD & AIDS 11, 371-4.
10. Sedjo, R. L., Roe, D. J., Abrahamsen, M. et al. (2002). Vitamin A, carotenoids, and risk of persistent oncogenic human papillomavirus infection. Cancer Epidemiology, Biomarkers & Prevention 11, 876-84.
11. Rampersaud, G. C., Bailey, L. B. & Kauwell, G. P. (2002). Relationship of folate to colorectal and cervical cancer: Review and recommendations for practitioners. Journal of the American Dietetic Association 102, 1273-82.
12. Badal, V., Chuang, L. S. H., Badal, S. et al. (2003). CpG methylation of human papillomavirus-16 DNA in cervical cancer cell lines and in clinical specimens: genomic hypomethylation correlates with carcinogenic progression. Journal of Virology 77, 6227-34.
13. Beerheide, W., Bernard. H. U., Tan Y. J. et al. (1999). Novel screens for potential drugs against cervical cancer identify zinc ejecting inhibitors of the HPV-16 E6 oncoprotein. Journal of the National Cancer Institute 91, 1211-20.
14. Underwood, M. R., Shewchuk, L. M., Hassell, A. M. et al. (2000). Searching for antiviral drugs for human papillomaviruses. Antiviral Therapy 5, 229-42.
15. Chen, Z., Kamath, P., Zhang, S. et al. (1996). Effects on tumor cells of ribozymes that cleave the RNA transcripts of human papillomavirus type 18. Cancer Gene Therapy 3, 18-23.
16. Butz, K., Ristriani, T., Hengstermann, A. et al. (2003). siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 22, 5938-45.
17. Tan, T. M. & Ting, R. C. (1995). In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes. Cancer Research 55, 4599-605.
18. Koutsky, L. A., Ault, K. A., Wheeler, C. M. et al. (2002). A controlled trial of a human papillomavirus type 16 vaccine. New England Journal of Medicine 347, 1645-51.
19. Chu, N. R., Wu, H. B., Wu, T. et al. (2000). Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clinical and Experimental Immunology 121, 216-25.